Literature DB >> 27194168

The Role of MDM2 Amplification and Overexpression in Tumorigenesis.

Jonathan D Oliner1, Anne Y Saiki2, Sean Caenepeel2.   

Abstract

Mouse double minute 2 (MDM2) is a critical negative regulator of the tumor suppressor p53, playing a key role in controlling its transcriptional activity, protein stability, and nuclear localization. MDM2 expression is up-regulated in numerous cancers, resulting in a loss of p53-dependent activities, such as apoptosis and cell-cycle arrest. Genetic amplification and inheritance of MDM2 promoter single-nucleotide polymorphisms (SNPs) are the two best-studied mechanisms for up-regulating MDM2 activity. This article provides an overview of these events in human cancer, highlighting the frequent occurrence of MDM2 amplification in sarcoma and the role of SNP309 and SNP285 in regulating MDM2 expression and cancer risk. The availability of large-scale genomic profiling datasets, like those from The Cancer Genome Atlas Research Network, have provided the opportunity to evaluate the consequences of MDM2 amplification and SNP inheritance across high-quality tumor samples from diverse cancer indications.
Copyright © 2016 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27194168      PMCID: PMC4888815          DOI: 10.1101/cshperspect.a026336

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  84 in total

1.  A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells.

Authors:  Wenwei Hu; Zhaohui Feng; Lan Ma; John Wagner; J Jeremy Rice; Gustavo Stolovitzky; Arnold J Levine
Journal:  Cancer Res       Date:  2007-03-15       Impact factor: 12.701

2.  The Cancer Genomics Hub (CGHub): overcoming cancer through the power of torrential data.

Authors:  Christopher Wilks; Melissa S Cline; Erich Weiler; Mark Diehkans; Brian Craft; Christy Martin; Daniel Murphy; Howdy Pierce; John Black; Donavan Nelson; Brian Litzinger; Thomas Hatton; Lori Maltbie; Michael Ainsworth; Patrick Allen; Linda Rosewood; Elizabeth Mitchell; Bradley Smith; Jim Warner; John Groboske; Haifang Telc; Daniel Wilson; Brian Sanford; Hannes Schmidt; David Haussler; Daniel Maltbie
Journal:  Database (Oxford)       Date:  2014-09-29       Impact factor: 3.451

3.  Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.

Authors:  Kathleen I Pishas; Susan J Neuhaus; Mark T Clayer; Andreas W Schreiber; David M Lawrence; Michelle Perugini; Robert J Whitfield; Gelareh Farshid; Jim Manavis; Steve Chryssidis; Bronwen J Mayo; Rebecca C Haycox; Kristen Ho; Michael P Brown; Richard J D'Andrea; Andreas Evdokiou; David M Thomas; Jayesh Desai; David F Callen; Paul M Neilsen
Journal:  Cancer Res       Date:  2013-12-13       Impact factor: 12.701

4.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

5.  MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner.

Authors:  Gareth L Bond; Kim M Hirshfield; Tomas Kirchhoff; Gabriella Alexe; Elisabeth E Bond; Harlan Robins; Frank Bartel; Helge Taubert; Peter Wuerl; William Hait; Deborah Toppmeyer; Kenneth Offit; Arnold J Levine
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

6.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.

Authors:  S N Jones; A E Roe; L A Donehower; A Bradley
Journal:  Nature       Date:  1995-11-09       Impact factor: 49.962

7.  MDM2 gene amplification in metastatic osteosarcoma.

Authors:  M Ladanyi; C Cha; R Lewis; S C Jhanwar; A G Huvos; J H Healey
Journal:  Cancer Res       Date:  1993-01-01       Impact factor: 12.701

Review 8.  The MDM2 gene amplification database.

Authors:  J Momand; D Jung; S Wilczynski; J Niland
Journal:  Nucleic Acids Res       Date:  1998-08-01       Impact factor: 16.971

9.  MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation.

Authors:  M Higashiyama; O Doi; K Kodama; H Yokouchi; T Kasugai; S Ishiguro; K Takami; T Nakayama; I Nishisho
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962

View more
  50 in total

1.  MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population.

Authors:  Lenora W M Loo; Chong Gao; Yurii B Shvetsov; Danielle R Okoro; Brenda Y Hernandez; Jill Bargonetti
Journal:  Breast Cancer Res Treat       Date:  2018-11-23       Impact factor: 4.872

Review 2.  Therapeutic opportunities in cancer therapy: targeting the p53-MDM2/MDMX interactions.

Authors:  Murali Munisamy; Nayonika Mukherjee; Levin Thomas; Amy Trinh Pham; Arash Shakeri; Yusheng Zhao; Jill Kolesar; Praveen P N Rao; Vivek M Rangnekar; Mahadev Rao
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

3.  Molecular docking of DS-3032B, a mouse double minute 2 enzyme antagonist with potential for oncology treatment development.

Authors:  Vítor Hugo Sales da Mota; Fabrício Freire de Melo; Breno Bittencourt de Brito; Filipe Antônio França da Silva; Kádima Nayara Teixeira
Journal:  World J Clin Oncol       Date:  2022-06-24

Review 4.  Small cell carcinoma of the bladder: the characteristics of molecular alterations, treatment, and follow-up.

Authors:  Yanling Wang; Qijun Li; Jing Wang; Mengting Tong; Haibo Xing; Yanan Xue; Hongming Pan; Changxing Huang; Da Li
Journal:  Med Oncol       Date:  2019-10-29       Impact factor: 3.064

Review 5.  The contributions of extrachromosomal DNA elements in neoplasm progression.

Authors:  Jiawei Hong; Shusen Zheng; Donghai Jiang
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

6.  The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets.

Authors:  Job van Riet; Harmen J G van de Werken; Edwin Cuppen; Ferry A L M Eskens; Margot Tesselaar; Linde M van Veenendaal; Heinz-Josef Klümpen; Marcus W Dercksen; Gerlof D Valk; Martijn P Lolkema; Stefan Sleijfer; Bianca Mostert
Journal:  Nat Commun       Date:  2021-07-29       Impact factor: 14.919

Review 7.  Targeting Apoptosis in Cancer.

Authors:  Puneet Singh; Bora Lim
Journal:  Curr Oncol Rep       Date:  2022-02-03       Impact factor: 5.075

Review 8.  Advancing targeted protein degradation for cancer therapy.

Authors:  Brandon Dale; Meng Cheng; Kwang-Su Park; H Ümit Kaniskan; Yue Xiong; Jian Jin
Journal:  Nat Rev Cancer       Date:  2021-06-15       Impact factor: 60.716

Review 9.  Mechanisms of TP53 Pathway Inactivation in Embryonic and Somatic Cells-Relevance for Understanding (Germ Cell) Tumorigenesis.

Authors:  Dennis M Timmerman; Tessa L Remmers; Sanne Hillenius; Leendert H J Looijenga
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

10.  p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a.

Authors:  Lei Duan; Ricardo E Perez; Ling Chen; Lothar A Blatter; Carl G Maki
Journal:  J Mol Cell Biol       Date:  2018-08-01       Impact factor: 8.185

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.